Phase 2 N=72 Citrulline in Severe Sepsis
Severe Sepsis · Acute Lung Injury
Primary: Vasopressor Dependency Index — 50.0; 44.4; 49.0 mmHg/catecholamine index — p=0.86
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia in Remission · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q)
Primary: Overall Survival of Patients on Busulfan and Etoposide Followed by Stem Cell Rescue and Aldesleukin — 14 Participants
Phase 2 N=87 Comparison of PET Amyloid Imaging in Japanese and Western Subjects
Mild Cognitive Impairment · Alzheimer's Disease · Healthy
Primary: Blinded Visual Assessment of Positron Emission Tomography (PET) Imaging and Clinical Diagnosis by Non-Japanese Readers — 23; 0; 2; 25 Participants
Phase 2 N=54 fMRI Study Examining Effects of D-cycloserine in Specific Phobia
Phobias
Primary: fMRI Brain Activations During Symptom Provocation — .200; .157; -.013; .036 percent signal change
Phase 2 N=13 Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration
Hypogonadism · Opioid-Related Disorders · Male Infertility
Primary: Serum Total Testosterone (Change From Baseline) — 322.5; 179.8 ng/mL
Phase 2 N=40 Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
Age-Related Macular Degeneration
Primary: Change in Edema From Baseline to Month 6 Central Subfield Thickness ) on Heidelberg Optical Coherence Topography — -30.0; 7.5 microns
Phase 2 N=730 Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV
HIV Infections
Primary: Number of Participants With Virologic Suppression — 274; 256; 160 Participants
Phase 2 N=71 Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
Relapsing Forms of Multiple Sclerosis
Primary: Percentage of Tetanus Responders (≥ 2-Fold Rise) at Day 28 Compared to Prevaccination Level — 73; 68 percentage of participants — p=0.692
Phase 2 N=58 Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Schizophrenia
Primary: Scale for the Assessment of Negative Symptoms (SANS) Total Score — 33.23; 36.63; 36.63; 30.07 units on a scale
Phase 2 N=48 A Two-Part Study of BOTOX® Therapy for Ischemic Digits
Raynaud's Disease
Primary: Percentage of Patient Reported Pain-free Days — 12; 48 percentage of pain free days
Phase 2 N=776 An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Asthma
Primary: Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 12: High Eosinophils -Intent to Treat (HEos-ITT) Population — 1.86; 1.77; 1.8; 1.87…
Phase 2 N=60 An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
Nasal Polyps
Primary: Change From Baseline in Bilateral Endoscopic Nasal Polyp Score (NPS) at Week 16 — 5.67; 5.87; 5.39; 3.97 score on a scale — p=0.0009
Phase 2 N=160 A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy
Type 2 Diabetes Mellitus
Primary: Reduction of HbA1c From Baseline — -0.85; -0.80; -0.46 Percent (%)
Phase 2 N=111 Dose Ranging of GSK2336805 in Combination Therapy
Hepatitis C, Chronic
Primary: Number of Participants Achieving eRVR — 23; 21; 9; 9 Participants
Phase 2 N=52 Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
B-cell Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Patients With Dose Limiting Toxicities (DLTs) — 2; 2; 4; 3 patients